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Background: The Chronic Kidney Disease Epidemiology Collaboration equation for estimation of glomerular
filtration rate (eGFRCKD-EPI) improves GFR estimation compared with the Modification of Diet in Renal Disease Study
equation (eGFRMDRD) but its association with mortality in a nationally representative population sample in the US
has not been studied.
Methods: We examined the association between eGFR and mortality among 16,010 participants of the Third
National Health and Nutrition Examination Survey (NHANES III). Primary predictors were eGFRCKD-EPI and eGFRMDRD.
Outcomes of interest were all-cause and cardiovascular disease (CVD) mortality. Improvement in risk categorization
with eGFRCKD-EPI was evaluated using adjusted relative hazard (HR) and Net Reclassification Improvement (NRI).
Results: Overall, 26.9% of the population was reclassified to higher eGFR categories and 2.2% to lower eGFR
categories by eGFRCKD-EPI, reducing the proportion of prevalent CKD classified as stage 3–5 from 45.6% to 28.8%.
There were 3,620 deaths (1,540 from CVD) during 215,082 person-years of follow-up (median, 14.3 years). Among
those with eGFRMDRD 30–59 ml/min/1.73 m
2, 19.4% were reclassified to eGFRCKD-EPI 60–89 ml/min/1.73 m
2 and
these individuals had a lower risk of all-cause mortality (adjusted HR, 0.53; 95% CI, 0.34-0.84) and CVD mortality
(adjusted HR, 0.51; 95% CI, 0.27-0.96) compared with those not reclassified. Among those with eGFRMDRD >60 ml/
min/1.73 m2, 0.5% were reclassified to lower eGFRCKD-EPI and these individuals had a higher risk of all-cause
(adjusted HR, 1.31; 95% CI, 1.01-1.69) and CVD (adjusted HR, 1.42; 95% CI, 1.01-1.99) mortality compared with those
not reclassified. Risk prediction improved with eGFRCKD-EPI; NRI was 0.21 for all-cause mortality (p< 0.001) and 0.22
for CVD mortality (p< 0.001).
Conclusions: eGFRCKD-EPI categories improve mortality risk stratification of individuals in the US population. If
eGFRCKD-EPI replaces eGFRMDRD in the US, it will likely improve risk stratification.
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Decreased kidney function is an independent risk factor
for mortality. While measured glomerular filtration rate
(GFR) remains the gold standard for assessing decreased
kidney function, in routine clinical practice, GFR is usu-
ally estimated from serum creatinine by the Modifica-
tion of Diet in Renal Disease (MDRD) Study equation
(eGFRMDRD). Understanding the association of eGFR
categories with clinical outcomes is an important aspect
of the chronic kidney disease (CKD) staging system. Ac-
curate classification of individuals with CKD can inform
healthcare utilization and therapeutic decision making
by reducing false positive diagnoses of CKD while cor-
rectly classifying those with CKD to appropriate risk
categories [1].
The Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation for estimation of GFR from serum
creatinine (eGFRCKD-EPI) improves GFR estimation com-
pared with the MDRD Study equation [2]. eGFRCKD-EPI,
as compared to eGFRMDRD, results in a lower preva-
lence of decreased eGFR [2]. Recent publications have
demonstrated that use of the CKD-EPI equation
results in reclassification of individuals previously
classified using eGFRMDRD to different eGFRCKD-EPI
categories with more appropriate risk stratification
[3-6]. However, the effect of this reclassification from
eGFRMDRD categories by CKD-EPI equation on long-
term risk prediction in a nationally representative
sample of the US population has not been described.
The objective of this study was to evaluate the effect
of reclassification using eGFRCKD-EPI on the estimated
risk of all-cause and cardiovascular disease (CVD)
mortality in the US population using data from the
Third National Health and Nutrition Examination
Survey (NHANES III) and relevant subgroups.
Methods
Study sample
NHANES III is a cross-sectional, multistage, stratified,
clustered probability sample of the noninstitutionalized
US civilian population conducted during 1988–1994 by
the National Center for Health Statistics (NCHS), a
branch of the Center for Disease Control and Prevention
[7]. In NHANES III, certain subgroups of the population
were oversampled including Mexican Americans, non-
Hispanic blacks and elderly persons to ensure adequate
sample sizes of these groups. We limited the study
population to 16,010 persons aged 17 years or older who
were examined at the mobile examination center (MEC),
were not missing serum creatinine data or covariates of
interest, and had available mortality follow-up. Mortality
follow-up was available for 99.9% of the eligible partici-
pants. The protocols for conduct of NHANES were
approved by the NCHS institutional review board andinformed consent was obtained from all participants.
Procedures were followed in accordance with ethical
standards of the Johns Hopkins School of Public Health
Office of Human Subjects Research and Institutional Re-
view Board.
Measurements
NHANES III procedures have been previously described
[7]. Briefly, standardized questionnaires were adminis-
tered at home and physical examination and laboratory
tests specimen collection was performed at the MEC.
Self-reported race/ethnicity was categorized as non-
Hispanic White, non-Hispanic Black, Mexican-American
or other. Smoking was defined as either active cigarette
smoking, having smoked >100 cigarettes in life, or never
having smoked. Participants were considered to have
diabetes mellitus if they reported being told by a doctor
that they had diabetes at a time other than pregnancy or
if they were taking insulin or oral hypoglycemic agents.
Cardiovascular disease (CVD) was considered to be
present at baseline if the participant reported being
informed by a doctor of prior heart attack, congestive
heart failure or stroke. Antihypertensive medication use
was based on self-report. Blood pressure (BP) was mea-
sured using standard techniques and reported as the
average of all systolic and diastolic readings. Participants
were advised to fast prior to specimen collection but
fasting was not required. Overall, 87% of the participants
had fasted for ≥ 6 hours prior to blood draw.
Serum creatinine was measured using a kinetic rate
Jaffe method. Serum creatinine measurements were
recalibrated to standardized creatinine measurements
obtained at the Cleveland Clinic Research Laboratory
(Cleveland, Ohio) as described previously [standard cre-
atinine = (0.960 x serum creatinine) – 0.184] [8]. We cal-
culated eGFR using the isotope dilution mass
spectrometry (IDMS)-traceable 4-variable MDRD Study
equation and the CKD-EPI equation [2,9]. There was no
difference in eGFRCKD-EPI based on fasting status
(0.98 ml/min/1.73 m2 lower in those fasting ≥6 hours;
p = 0.14). We categorized eGFR into the following clinic-
ally relevant categories: ≥120, 90–119, 60–89, 30–59 and
<30 ml/min/1.73 m2. Within each category of
eGFRMDRD, individuals were reclassified into three
groups based on eGFRCKD-EPI: a) higher eGFRCKD-EPI
category; (b) same eGFR category by both eGFRMDRD
and eGFRCKD-EPI, and; (c) lower eGFRCKD-EPI category.
C-reactive protein (CRP) was measured by latex-
enhanced nephelometry (Dade Behring). CRP level was
categorized as either undetectable by the assay
(<0.22 mg/dL), minimal (0.22-0.99 mg/dL) or elevated
(≥1.0 mg/dL). Urinary albumin level was measured by
solid-phase fluorescence immunoassay, and urinary creatin-
ine level was measured by the modified kinetic method of
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(Beckman Coulter, Inc., Fullerton, California). Albuminuria
was expressed as urinary albumin-to-creatinine ratio (ACR)
and categorized into 3 categories; <30 mg/g, 30–299 mg/g
and ≥300 mg/g.
Causes of death
Causes of death were obtained using the NHANES III
Linked Mortality Public-use File [10]. This file contains
mortality follow-up data on NHANES III participants
obtained via National Death Index (NDI) linkage
through December 31, 2006. Mortality ascertainment
is performed using probabilistic matching between
NHANES III and NDI using previously validated meth-
ods [10]. Cause of death coding for all U.S. deaths occur-
ring prior to 1999 followed the 9th revision of the
International Statistical Classification of Diseases, Injur-
ies, and Causes of Death (ICD-9) guidelines, while all
deaths after 1998 followed the 10th revision of the Inter-
national Statistical Classification of Diseases, Injuries,
and Causes of Death (ICD-10) guidelines. All deaths oc-
curring prior to 1999 were recoded from ICD-9 to com-
parable ICD-10 (I) based cause of death groups [11]. We
defined cardiovascular disease mortality using the fol-
lowing cause of death groups: 056 (hypertensive heart
disease [I11]), 057 (hypertensive heart and renal disease
[I13]), 058–063 (ischemic heart diseases [I20-I25]), 067
(heart failure [I50]), 068 (valvular heart diseases and car-
diomyopathy [I26-I28, I34-I38, I42-I49, I51]), 069 (essen-
tial hypertension and hypertensive renal disease [I10,
I12]), 070 (cerebrovascular disease [I60-I69]), and 071
(atherosclerosis [I70]).
Statistical analysis
All analyses were performed using 6-year MEC sampling
weights provided by the National Center for Health Sta-
tistics that account for the complex survey design of
NHANES III as well as probabilities for non-response.
Analyses were performed using survey (svy) commands
Stata 10.1 and 11.2. (Stata Corp, www.stata.com) Base-
line characteristics were compared across eGFR categor-
ies and reclassification status of the participants.
Survival analysis techniques were used to analyze the
risk of all-cause and CVD mortality. Individuals who
were alive on December 31, 2006 were censored in the
analyses. Modified Cox proportional hazards regression
was used to model the risk of death across eGFR and re-
classification categories. Hazard ratios (HR) were calcu-
lated to assess risk of death after adjustment for age,
race/ethnicity, sex, body mass index, systolic and dia-
stolic BP, antihypertensive medication use, history of dia-
betes and CVD, smoking status, serum total cholesterol,
ACR categories and CRP categories. Poisson regression
was used to calculate and display incidence rates witheGFR modeled as a restricted cubic spline with knots at
30, 45, 60, 90 and 120 ml/min/1.73 m2.
Reclassification
To assess reclassification we calculated net reclassifica-
tion improvement (NRI) [12]. Net reclassification im-
provement (NRI) is a statistic that allows calculation of
the effect of reclassification of individuals from one dis-
ease category to the other. It is a difference of two ratios;
clinically correct reclassification minus clinically incor-
rect classification. The range of this difference is from
−1 to +1 with a negative number reflecting incorrect re-
classification and a positive number indication correct
reclassification.
For NRI calculations we excluded individuals with
eGFR ≥120 ml/min/1.73 m2 by either equation as the
high eGFR in this group reflects low serum creatinine
likely from malnutrition, intercurrent illness and low
muscle mass [3]. To calculate NRI, we first created
cross-tabulation of participants in eGFRMDRD and
eGFRCKD-EPI categories stratified by the outcome status
(alive or dead). We then calculated the proportion of
individuals in each category of eGFRMDRD that are re-
classified by eGFRCKD-EPI. Clinically correct reclassifica-
tion was defined as: proportion of participants
reclassified to higher eGFR category by eGFRCKD-EPI
among those who are alive + the proportion of partici-
pants reclassified to lower eGFR category by eGFRCKD-
EPI among those who died. Clinically incorrect reclassifi-
cation was defined as: proportion of participants reclas-
sified to higher eGFR category by eGFRCKD-EPI among
those who died + the proportion of participants reclassi-
fied to lower eGFR category by eGFRCKD-EPI among
those who are alive. NRI = clinically correct reclassifica-
tion – clinically incorrect reclassification. Statistical sig-
nificance for NRI was calculated using bootstrapping
with replacement. To account for the confounding effect
of age, sex and race on outcomes, we also calculated
stratum-specific NRI in these subgroups.
Results
Baseline characteristics
The baseline characteristics of the participants stratified
by reclassification status by eGFRCKD-EPI are presented
in Table 1. Overall, the number of participants (popula-
tion %) reclassified were as follows: 3,464 (26.9%) of the
participants were reclassified to a higher eGFR category,
559 (2.2%) were reclassified to a lower eGFR category
and 11,987 (70.8%) were not reclassified. There was only
1 participant with eGFRMDRD <30 ml/min/1.73 m
2 who
was reclassified upward (data not presented in Table1).
Individuals reclassified to higher eGFRCKD-EPI categories
were more likely to be younger, female, had lower preva-
lence of diabetes and CVD, and had lower BP,
Table 1 Baseline characteristics of 16,010 NHANES III (1988–1994) participants stratified by eGFRMDRD and eGFRCKD-EPI
EGFRMDRD ≥120 90-119 60-89 30-59 <30
(No. of participants) a (2,729) (6,604) (5,606) (1,015) (56)
EGFRCKD-EPI ≥120 90-119 ≥120 90-119 60-89 90-119 60-89 30-59 60-89 30-59 <30 <30
Number of
participants a (%) b
2,416 312 d 1,473 4,969 162 1,870 3,664 72 120 883 12 55 e




0.64 0.59 0.76 0.79 0.70 0.87 0.94 1.07 1.07 1.26 1.97 2.76
(0.004) (0.01) (0.003) (0.002) (0.01) (0.004) (0.004) (0.03) (0.02) (0.02) (0.11) (0.20)
EGFRMDRD
(ml/min/1.73 m2)
138 131 112 100 98 85 74 61 58 49 31 23
(0.63) (0.72) (0.17) (0.18) (0.28) (0.09) (0.13) (0.09) (0.13) (0.27) (0.32) (0.88)
EGFRCKD-EPI
(ml/min/1.73 m2)
133 112 124 109 87 96 79 59 63 50 29 22
(0.36) (0.51) (0.14) (0.12) (0.27) (0.18) (0.20) (0.13) (0.20) (0.30) (0.24) (0.92)
Age (years) 26 (0.2) 53 (0.8) 28 (0.3) 39 (0.2) 79 (0.5) 40 (0.5) 59 (0.6) 83 (1.0) 56 (1.11) 72 (0.74) 81 (2.12) 72 (1.75)
Age< 65 years,
N (%) a b
2,415 247 1,473 4,614 0 1,754 1,717 0 100 115 0 12
(99.9) (85.8) (100) (96.4) (95.8) (61.3) (83.8) (18.0) (16.9)
Male (%) 40 55 44 53 56 46 49 60 24 40 72 35
Race/Ethnicity (%)
Non-Hispanic White 52 67 65 74 85 86 86 86 90 86 90 73
Non-Hispanic Black 25 9 19 11 7 4 7 13 1 8 9 18
Mexican American 13 10 8 6 2 4 2 1 2 1 1 2
Other 11 13 9 10 7 6 6 1 6 5 0 8
Ever or Current
Smoker (%)
45 68 46 56 47 51 54 43 57 55 84 56
Diabetes (%) 3 13 <1 3 11 3 8 6 14 15 27 26
Prior CVD (%) <1 <1 <1 3 16 3 10 22 13 26 73 35
Body Mass Index
(kg/m2)
25 27 25 26 25 26 27 25 29 28 25 26
(0.23) (0.75) (0.20) (0.14) (0.26) (0.20) (0.15) (0.45) (0.68) (0.24) (1.02) (1.18)
Systolic Blood Pressure,
mm Hg
112 130 112 119 145 118 131 143 130 143 150 145
(0.46) (1.90) (0.34) (0.31) (1.86) (0.45) (0.59) (1.99) (2.22) (1.03) (6.01) (3.66)
Diastolic Blood Pressure,
mm Hg
68 78 69 74 73 75 76 72 76 75 71 73
(0.41) (0.95) (0.35) (0.28) (1.05) (0.32) (0.25) (1.14) (0.85) (0.49) (2.11) (2.98)
Antihypertensive
medication use (%)
4 26 2 10 32 10 27 44 36 60 75 74
Total Cholesterol
(mg/dl)
183 217 181 198 208 204 217 213 230 232 209 230
(1.69) (4.92) (1.68) (1.14) (3.82) (1.57) (1.21) (5.49) (4.65) (2.81) (10.31) (14.24)
CRP (mg/dl; %)
<0.22 73 58 80 75 71 76 67 62 64 52 29 42
0.22-0.99 19 29 14 19 22 19 25 28 23 32 12 40
≥1.00 9 13 6 6 7 5 8 10 13 16 59 18
ACR (mg/g; %)
<30 93 84 93 94 74 95 89 78 83 70 9 34
30-300 6 11 7 5 25 5 10 18 15 23 68 20
≥300 <1 5 <1 <1 17 1 1 4 3 7 23 46
Abbreviations: CVD, Cardiovascular Disease; eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease Study; CKD-EPI, Chronic Kidney
Disease Epidemiology Collaboration; CRP, C-reactive protein; ACR, albumin-to-creatinine ratio.
Note: Conversion factors for units: low- and high-density lipoprotein cholesterol in mg/dL to mmol/L, ×0.02586; triglycerides in mg/dL to mmol/L, ×0.01129;
creatinine in mg/dL to μmol/L, ×88.4; eGFR in mL/min/1.73 m2 to mL/s/1.73 m2, ×0.01667; albumin-creatinine ratio in mg/g to mg/mmol, divide by 8.84.
a Participant numbers are unweighted N.
b Percent represents the population percent representative of the non-institutionalized US population; total may not equal 100% due to rounding.
c Values presented are population % for categorical variables and mean (linearized standard error) for continuous variables.
d One 86 year old Mexican-American female with serum creatinine=0.488 mg/dL had eGFRMDRD=120 ml/min/1.73 m
2 and eGFRCKD-EPI 89 ml/min/1.73 m
2 (data not shown).
e One 64 year old Mexican-American female with serum creatinine=1.736 had eGFRMDRD=29.5 ml/min/1.73 m
2 and eGFRCKD-EPI = 30.6 ml/min/1.73 m
2 (data not shown).
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were much more pronounced at lower eGFR categories
(<60 ml/min/1.73 m2). Among participants with
eGFRMDRD <120 ml/min/1.73 m
2, no participants below
65 years were reclassified to a lower eGFRCKD-EPI
category.
Estimated GFR and the risk of death
There were 3,620 deaths over 215,082 person-years of
follow-up (median, 14.3 years). The weighted unadjusted
incidence rate for all-cause mortality was higher for
eGFRCKD-EPI compared with eGFRMDRD below 90 ml/
min/1.73 m2 (Figure 1a). Within categories of eGFR, the
hazards for all-cause mortality adjusted for demographic
characteristics, comorbidities, CRP and ACR were higher
for eGFRCKD-EPI categories compared with eGFRMDRD
categories (Table 2). With both eGFR equations, there
was U-shaped association with mortality with higher risk
of death for eGFR above 120 ml/min/1.73 m2 and below
60 ml/min/1.73 m2 compared with eGFR 90–119 ml/
min/1.73 m2. There were few individuals with eGFR
<30 ml/min/1.73 m2 (eGFRMDRD, n = 56; eGFRCKD-EPI,
n = 67) and few deaths in individuals with eGFR
≥120 ml/min/1.73 m2 (eGFRMDRD, n = 228; eGFRCKD-EPI,
n = 179). Overall, the trends for association between
eGFR categories and CVD mortality (n = 1,540) were
very similar to all-cause mortality (Figure 1b and
Table 2).
Reclassification by eGFRCKD-EPI and the risk of death
Figure 2 displays the unadjusted cumulative incidence of
death with reclassification by eGFRCKD-EPI. Those classi-
fied upwards to a higher eGFRCKD-EPI category had
lower cumulative incidence of mortality while those re-

































Figure 1 Unadjusted Incidence Rates of Mortality with eGFRMDRD and
Cause Mortality. b: Cardiovascular Disease Mortality.higher cumulative incidence of death compared with
those not reclassified. Overall, compared with no reclas-
sification, the hazard ratio (HR) of all-cause mortality
with reclassification to a higher eGFRCKD-EPI category
was 0.34 (95% CI, 0.28-0.41) and with reclassification to
a lower eGFRCKD-EPI category was 3.56 (95% CI, 3.04-
4.16). After adjustment for age, sex and race/ethnicity,
the HR was 0.91 (95% CI, 0.75-1.10) and 1.28 (95% CI,
1.11-1.48) for reclassification to a higher and lower
eGFRCKD-EPI category, respectively.
Table 3 displays the adjusted HR for all-cause and
CVD mortality with reclassification by eGFRCKD-EPI
within categories of eGFRMDRD. Among those classified
as eGFRMDRD 30–59 ml/min/1.73 m
2, reclassification to
a higher eGFRCKD-EPI category was associated with a
47% lower hazard of death compared with those not re-
classified (HR adjusted for demographic characteristics,
comorbidities, CRP and albuminuria, 0.53; 95% CI, 0.34-
0.84). There were very few individuals (n = 12) with
eGFRMDRD 30–59 ml/min/1.73 m
2 who were reclassified
to a lower eGFRCKD-EPI category.
Those who were reclassified upwards to eGFRCKD-EPI
≥60 ml/min/1.73 m2 from eGFRMDRD 30–59 ml/min/
1.73 m2 had similar risk of all-cause mortality as those
with eGFR ≥60 ml/min/1.73 m2 by both equations
(adjusted HR, 1.05; 95% CI, 0.62-1.77). Reclassification
from eGFRMDRD category 60–89 ml/min/1.73 m
2 to a
lower eGFRCKD-EPI category (30–59 ml/min/1.73 m
2)
was associated with a higher risk of death (adjusted HR,
1.31; 95% CI, 1.01-1.69) compared with those not reclas-
sified. There were no significant differences noted in all-
cause mortality among individuals reclassified in
eGFRCKD-EPI categories 90–119 and ≥120 ml/min/

































eGFRCKD-EPI in the US Population: NHANES III (1988–1994). a: All-
Table 2 Adjusteda hazard ratio (95% Confidence interval) of all-Cause and cardiovascular disease mortality, by eGFR
categories among 16,010 participants of NHANES III (1988–1994) with follow-up till December 31, 2006
Categories of eGFR (ml/min/1.73 m2)
≥ 120 90-119 60-89 30-59 < 30
All-Cause Mortality
EGFRCKD-EPI Participants, N 3,889 7,151 3,947 956 67
Deaths, N 179 921 1,686 775 59
HR 2.05 Reference 0.97 1.39 1.38
(95% CI) (1.55-2.71) (0.86-1.10) (1.17-1.65) (0.88-2.16)
EGFRMDRD Participants, N 2,729 6,604 5,606 1,015 56
Deaths, N 228 805 1,788 750 49
HR 1.70 Reference 0.94 1.31 1.96
(95% CI) (1.36-2.14) (0.84-1.05) (1.11-1.56) (1.11-3.44)
CVD Mortality
EGFRCKD-EPI Participants, N 3,889 7,151 3,947 956 67
Deaths, N 41 303 755 412 29
HR 2.70 Reference 1.05 1.49 1.64
(95% CI) (1.54-4.73) (0.87-1.26) (1.16-1.92) (1.02-2.65)
EGFRMDRD Participants, N 2,729 6,604 5,606 1,015 56
Deaths, N 64 278 774 401 23
HR 1.53 Reference 0.95 1.32 2.17
(95% CI) (0.96-2.45) (0.79-1.13) (0.99-1.78) (1.18-3.98)
Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease Study; CKD-EPI, Chronic Kidney Disease Epidemiology
Collaboration; CVD, Cardiovascular Disease.
a Adjusted for age, sex, race/ethnicity, prior CVD, diabetes, smoking, systolic and diastolic blood pressure, use of antihypertensive medications, body mass index,
cholesterol, C-reactive protein category and albumin-to-creatinine ratio category.
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To evaluate the effect of reclassification on mortality, we
restricted our analysis to individuals with eGFRMDRD
and eGFRCKD-EPI <120 ml/min/1.73 m
2. Table 4 pre-
sents the NRI for all-cause and CVD mortality. The
overall NRI for eGFRCKD-EPI for all-cause mortality was
0.21 (p< 0.001) and for CVD mortality was 0.22
(p< 0.001). In age stratified analyses, the NRIs was lower
as expected but remained substantial for participant age
>65 years (0.14 for all-cause and 0.09 for CVD,
p< 0.001). The NRI was also significant stratified by sex
and most ethnicity groups as well as stratified by sex
and limited to older participants (Additional file 1 Table
S1, NRI 0.09 for men and 0.15 for women age
>65 years).
Discussion
In this study of a representative sample of US adults
during 18 years of follow-up, eGFRCKD-EPI improved risk
stratification. Among those classified as eGFRMDRD 30–
59 ml/min/1.73 m2, 19.4% were reclassified to eGFR
>60 ml/min/1.73 m2 by the CKD-EPI equation and this
upward reclassification was associated with 47% lower
risk of all-cause mortality and 49% lower risk of CVD
mortality compared with individuals with eGFR 30–
59 ml/min/1.73 m2 by both the MDRD Study and CKD-EPI equations. Among those with eGFRMDRD 60–89 ml/
min/1.73 m2, 0.5% were reclassified downwards to eGFR
30–59 ml/min/1.73 m2 by the CKD-EPI equation and
this downward classification was associated with 31%
higher risk of all-cause mortality and 42% higher risk of
CVD mortality. Overall, CKD-EPI equation significantly
improved risk prediction for both all-cause and CVD
mortality. The better risk categorization by the CKD-EPI
equation was observed particularly in those older than
65 years at baseline.
CKD-EPI equation improves GFR estimation com-
pared with the MDRD Study equation and eGFRCKD-EPI
is significantly more accurate than eGFRMDRD above and
below 60 ml/min/1.73 m2 as well as across racial and
ethnic subgroups [2,13]. The properties of the CKD-EPI
equation result in higher eGFR in younger individuals,
whites and females. In NHANES, we noted that reclassi-
fication moved individuals with higher comorbidities to
a lower eGFRCKD-EPI category and individuals with lower
comorbidities to higher eGFRCKD-EPI categories. In the
clinically important CKD stage 3 (eGFRMDRD 30–59 ml/
min/1.73 m2), almost 20% of the population was reclassi-
fied to a higher eGFRCKD-EPI category. In unadjusted and
adjusted analyses, this reclassification was associated
with a lower risk of death, suggesting that eGFRCKD-EPI
in this range may have clinical significance even without
Figure 2 Cumulative Incidence of All-Cause Mortality with Reclassification by eGFRCKD-EPI within eGFRMDRD Categories in the US
Population: NHANES III (1988–1994). a: Reclassification within eGFRMDRD Category ≥120 ml/min/1.73 m
2. b: Reclassification within eGFRMDRD
Category 90–119 ml/min/1.73 m2. c: Reclassification within eGFRMDRD Category 60–89 ml/min/1.73 m
2. d: Reclassification within eGFRMDRD
Category 30–59 ml/min/1.73 m2.
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have important implications for both individual clinical
risk stratification and screening.
A number of recent studies have demonstrated that the
use of eGFRCKD-EPI results in improvement in risk classi-
fication of individuals. In the Australian Diabetes, Obes-
ity and Lifestyle (AusDiab) Study, 25% of the participants
with eGFRMDRD <60 ml/min/1.73 m
2 were reclassified to
higher eGFRCKD-EPI category [4]. The risk of death in
individuals with eGFRMDRD <60 ml/min/1.73 m
2 reclas-
sified to eGFR >60 ml/min/1.73 m2 by the CKD-EPI
equation was similar to those with eGFRMDRD ≥60 ml/
min/1.73 m2 (HR, 1.01; 95% CI, 0.62-1.97). In the Ath-
erosclerosis Risk in Communities (ARIC) Study, a pro-
spective cohort of 45–64 year old whites and African-
Americans from 4 US communities (N= 13,905), reclassi-
fication from eGFRMDRD 30–59 ml/min/1.73 m
2 to
eGFRCKD-EPI 60–89 ml/min/1.73 m
2 was associated with
a lower risk of all-cause mortality in the unadjusted mod-
els but was no longer significant after adjustment for age,
sex and race. NRI for all-cause mortality was 0.095(p< 0.001) [3]. Among participants of Kidney Early
Evaluation Program (KEEP), a US screening program for
individuals at high risk of chronic kidney disease, 17.5%
were reclassified to higher eGFR categories and 2.7% to
lower categories. Upward reclassification was associated
with lower mortality, downward reclassification was asso-
ciated with higher mortality and NRI was 0.159 [6]. In a
post hoc analysis of the VALIANT trial, eGFRCKD-EPI cat-
egories improved risk stratification and the NRI for the
composite end point of CVD death, recurrent myocardial
infarction, heart failure, or stroke was 0.087 [5]. Our
study extends these findings in a study with results
generalizable to the US population and quantifies the im-
provement in risk stratification in African-Americans
and Mexican-Americans.
We used NRI to assess the improvement in risk pre-
diction with CKD-EPI equation compared with the
MDRD Study equation. The improvement in risk predic-
tion is expected to be relatively small as both equations
use the same variables and have the inherent limitation
of serum creatinine as a marker of GFR. Traditional
Table 3 Reclassification and adjusted hazard ratiosa of all-cause and cardiovascular disease mortality by eGFR
categories determined using the MDRD and the CKD-EPI study equation: NHANES III (1988–1994) - follow-up till
December 31, 2006
EGFRCKD-EPI Categories
EGFRMDRD Categories >120 90-119 60-89 30-59 <30
>120
Reclassified, N b (%)c 2,416 (88.3) 312 (11.7)
All-Cause Mortality
Deaths, N b 126 101
HR (95% CI) REFERENCE 0.57 (0.26-1.26)
CVD Mortality
Deaths b 28 36
HR (95% CI) REFERENCE 0.37 (0.15-0.94)
90-119
Reclassified, N b (%)c 1,473 (20.2) 4,969 (78.4) 162 (1.4)
All-Cause Mortality
Deaths, N b 53 604 148
HR (95% CI) 1.42 (0.85-2.37) REFERENCE 1.39 (0.94-2.07)
CVD Mortality
Deaths b 13 193 72
HR (95% CI) 2.95 (1.03-8.42) REFERENCE 1.79 (0.94-3.39)
60-89
Reclassified, N b (%)c 1,870 (42.9) 3,664 (56.6) 72 (0.5)
All-Cause Mortality
Deaths, N b 216 1,506 66
HR (95% CI) 1.13 (0.91-1.42) REFERENCE 1.31 (1.01-1.69)
CVD Mortality
Deaths b 74 669 31
HR (95% CI) 1.02 (0.69-1.50) REFERENCE 1.42 (1.01-1.99)
30-59
Reclassified, N b (%)c 120 (19.4) 883 (79.5) 12 (1.1) d
All-Cause Mortality
Deaths, N b 31 708 11
HR (95% CI) 0.53 (0.34-0.84) REFERENCE N/A
CVD Mortality
Deaths b 14 381 6
HR (95% CI) 0.51(0.27-0.96) REFERENCE N/A
Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease Study; CKD-EPI, Chronic Kidney Disease Epidemiology
Collaboration; HR, Hazard Rate; CVD, cardiovascular disease; N/A, not applicable.
a Adjusted for age, sex, race/ethnicity, prior CVD, systolic or diastolic blood pressure, use of antihypertensive medications, diabetes status, smoking status, body
mass index, cholesterol, CRP category and albumin-to-creatinine ratio category.
b Numbers represent crude (un-weighted) participant number.
c Percent represents the population percent representative of the non-institutionalized US population; total may not equal 100% due to rounding.
d HR not presented as there are less than 30 people in the cell.
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receiver-operating-characteristic curve (AUC) require
large independent associations, often over 2–3 fold, to
result in meaningful improvement in AUC [14-16]. The
NRI is particularly well suited when categories are asso-
ciated with clinical action as is the case for estimated
GFR. The NRI was lower in younger age groups despitehigh reclassification rates, possibly since death rates are
low at younger age. Among older age groups (>65 years),
NRIs were quite high (0.14 for all-cause and 0.09 for
CVD mortality) despite reclassification being lower (11%
compared to >30% in younger ages). Notably, the NRIs
in the older age group remain significant even after
stratification with sex or race/ethnicity. In contrast to
Table 4 Net reclassification improvement by the CKD-EPI
equation among participants with eGFR <120 ml/min/






All-cause (CVD) All-cause CVD
Overall 11,808 (24.1%) 3,339 (1,463) 0.2073*** 0.2216***
By Age Categories
17-44 4,822 (30.3%) 208 (58) 0.0216 −0.0883
45-64 3,491 (21.8%) 715 (258) −0.0146 −0.0006
≥65 3,495 (11.4%) 2,416 (1,147) 0.1362*** 0.0943***
By Sex
Male 5,839 (22.1%) 1,844 (796) 0.2077*** 0.2277***
Females 5,969 (26.0%) 1,495 (667) 0.2063*** 0.2157***
By Race/Ethnicity
NH Whites 5,736 (25.7%) 1,957 (903) 0.2258*** 0.2368***
NH Blacks 2,701 (12.8%) 710 (290) 0.1245*** 0.1229***
Mex-Am 2,868 (20.2%) 594 (239) 0.0648** 0.0682*
Others 503 (20.2%) 78 (31) 0.1427* 0.2559*** b
Abbreviations: eGFR, estimated glomerular filtration rate; MDRD, Modification
of Diet in Renal Disease Study; CKD-EPI, Chronic Kidney Disease Epidemiology
Collaboration; NRI, Net Reclassification Improvement; NH, Non-Hispanic; Mex-
Am, Mexican-American.
a Reclassification to a different eGFR category by CKD-EPI equation. Number
represents the number of participants; Population % is representative of the
non-institutionalized US population.
b NRI estimates less precise as there are <50 events in this cell.
* p< 0.05; ** p< 0.01; *** p< 0.001.
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statistically significant in those 45–64 years of age. These
discrepant findings require further study across a range
of populations.
We noted increased risk of all-cause and CVD death
among individuals with eGFR ≥120 ml/min/1.73 m2 by
either equation compared with eGFR 90–119 ml/min/
1.73 m2 after the adjustment for potential confounders
(Table 2). The HR was higher for eGFRCKD-EPI than for
eGFRMDRD in this category. This association has been
noticed in previous studies and replicates the well-
known U- shaped relationship between serum creatinine
and mortality. This U-shape likely includes components
of low muscle mass and hyperfiltration which cannot be
separated using only serum creatinine as a marker of
GFR. They persist despite the inclusion of a spline term
for serum creatinine in the CKD-EPI equation which
reduces the very high eGFRs calculated using the MDRD
Study equation.
The strengths of our study includes its large sample
size, prospective design, large sample of racial/ethnic mi-
norities, broad age range of the population, rigorous data
collection and extensive information on covariates, prior
work to standardize serum creatinine, measurement of
ACR and CRP, near-complete mortality follow-up usingthe NDI and large number of events during the follow-
up period. The results of our study are generalizable to
the non-institutionalized population of the U.S. Some
limitations of our study also deserve mention. GFR was
not measured but was estimated using serum creatinine
and not all participants were fasting prior to serum cre-
atinine measurement. Nonetheless, serum creatinine and
estimated GFR are routinely used measures of kidney
function in clinical practice and our data reflect com-
mon clinical information. We had relatively few indivi-
duals with eGFRMDRD <30 ml/min/1.73 m
2. Cause of
death was ascertained via NDI linkage of NHANES III
data and not independently adjudicated and there is po-
tential of misclassification of CVD mortality. Import-
antly, we did not have information about kidney failure
requiring renal replacement therapy, an important out-
come that deserves examination in future studies.
Conclusion
The CKD-EPI equation for estimating GFR predicts risk
at least as well as the MDRD Study equation in the gen-
eral US population and improves risk classification of
individuals, particularly among those older than 65 years.
Our data, in conjunction with previously reported stud-
ies, suggest that adoption of CKD-EPI equation for
eGFR reporting may improve clinical risk stratification.
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